In assessing the sixteen biotechs making their public debuts over the past six months, investors clearly favor companies specializing in development, not discovery. What's more, investors especially prefer those development firms with late-stage products, lots of cash, and possibly even a sizable out-licensing deal.
By Heather Slowik
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
